Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel medicines. Its Recursion operating system enables advanced machine learning approaches to reveal drug candidates, mechanisms of action, novel chemistry, and potential toxicity, with the eventual goal of decoding biology and advancing new therapeutics that radically improve people's lives. The company was founded by Blake Borgeson, Christopher C. Gibson, and Dean Y. Li on November 5, 2013 and is headquartered in Salt Lake City, UT.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NVIDIA

ARM Holdings PLC

SoundHound AI Inc

Serve Robotics Inc

You're doing something right if your company is worth $2.6 trillion like Nvidia. And it's worth looking at the companies Nvidia invests in.

Nvidia Owns 4 Stocks — One Is Doing Even Better Than It Is

Ginkgo Bioworks Holdings

Cathie Wood likes to invest in risky biotech stocks. Ginkgo Bioworks has ambitions to disrupt biopharma manufacturing.

2 Cathie Wood Biotech Stocks That Could Be Worth the Risk

Dr. Hershberg is a current board member with over 25 years of experience as a physician, scientist, and entrepreneur Dr. Hershberg is a current board member with over 25 years of experience as a physician, scientist, and entrepreneur

Recursion Appoints Robert Hershberg M.D., Ph.D, as New Chair of the Board

Viking Therapeutics

Viking Therapeutics is looking to make noise in a fast-growing therapeutic area. Recursion Pharmaceuticals' approach could change the way we develop drugs.

2 Stocks That Could 10x by 2035

Recursion Pharmaceuticals (RXRX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Here is What to Know Beyond Why Recursion Pharmaceuticals, Inc. (RXRX) is a Trending Stock

Schrodinger 

Some high-tech biotechs claim to be "TechBio" companies. The term signals the use of an automation-heavy approach to biotech.

What's the Difference Between Biotech Stocks and TechBio Stocks?

BioHive-2, an NVIDIA DGX SuperPOD with NVIDIA DGX H100 systems, ranked #35 in the TOP500 list of the most powerful supercomputers in the world across all industries as of May 2024. BioHive-2, an NVIDIA DGX SuperPOD with NVIDIA DGX H100 systems, ranked #35 in the TOP500 list of the most powerful supercomputers in the world across all industries as of May 2024.

Recursion Announces Completion of NVIDIA-Powered BioHive-2, the Largest Supercomputer in Pharmaceutical Industry

Recursion Pharmaceuticals, an AI-focused biotech, makes up more than 5% of one of Ark Invest's ETFs. The company's approach looks promising, but it has yet to produce the kinds of results investors want.

Cathie Wood Is Buying This Under-the-Radar AI Stock

Recursion Pharmaceuticals reported higher revenue than analysts expected for Q1 2024. The company has made significant advancements in its clinical pipeline, with multiple Phase 2 trials expected to read out starting in Q3 2024.

Recursion Pharma's Q1 Earnings Beat Estimates

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX ) Q1 2024 Earnings Conference Call May 9, 2024 5:00 PM ET Company Participants Chris Gibson - Co-Founder & Chief Executive Officer Conference Call Participants Chris Gibson Hi, everybody. I'm Chris Gibson, Co-Founder and CEO of Recursion, and I'm so delighted you've joined us today for our Q1 2024 Earnings Call -- L(earnings) Call, as we call it.

Recursion Pharmaceuticals, Inc. (RXRX) Q1 2024 Earnings Call Transcript

Recursion Pharmaceuticals (RXRX) came out with a quarterly loss of $0.39 per share versus the Zacks Consensus Estimate of a loss of $0.43. This compares to loss of $0.34 per share a year ago.

Recursion Pharmaceuticals (RXRX) Reports Q1 Loss, Tops Revenue Estimates

SALT LAKE CITY, May 09, 2024 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today reported business updates and financial results for its first quarter ending March 31, 2024.

Recursion Provides Business Updates and Reports First Quarter 2024 Financial Results

In the closing of the recent trading day, Recursion Pharmaceuticals (RXRX) stood at $8.84, denoting a +0.57% change from the preceding trading day.

Recursion Pharmaceuticals (RXRX) Increases Yet Falls Behind Market: What Investors Need to Know

Zacks.com users have recently been watching Recursion Pharmaceuticals (RXRX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Recursion Pharmaceuticals, Inc. (RXRX) is Attracting Investor Attention: Here is What You Should Know

SALT LAKE CITY, May 02, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, announced today it will provide business updates and report its first quarter 2024 financial results on Thursday, May 9, 2024, following the close of the financial markets. Additionally, Recursion will host its quarterly L(earnings) Call on May 9, 2024 at 5:00 pm Eastern Time / 3:00 pm Mountain Time.

Recursion to Report First Quarter 2024 Business Updates and Financial Results on May 9

SALT LAKE CITY, May 01, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced its participation in the following investor conferences:

Recursion to Participate in Upcoming Investor Conferences

Nvidia's equity portfolio ballooned beyond $100 million in the fourth quarter, requiring public disclosures. Just two stocks make up nearly all of its portfolio.

Nvidia Owns a 3.4% Stake in This Innovative Artificial Intelligence (AI) Stock Cathie Wood Loves

Exelixis

Iovance Biotherapeutics

Biotech stocks are notorious for being some of the most volatile and unpredictable on the market. With clinical trials and FDA approvals creating potential leaps or falls in what seems like an instant, there is no denying the risk involved.

The Top 3 Biotech Stocks to Buy in April 2024

Recursion Pharmaceuticals (RXRX) closed at $7.84 in the latest trading session, marking a -1.26% move from the prior day.

Recursion Pharmaceuticals (RXRX) Declines More Than Market: Some Information for Investors

Oncology's future prominently features the kind of autoimmune R&D work that Iovance is doing. Helped by new technology, Recursion is using artificial intelligence to develop new drugs.

3 Millionaire-Maker Biotech Stocks

Sana Biotechnology

Biotech stocks are having a relatively strong year as investors focus on the growing M&A in the healthcare space. Johnson & Johnson is acquiring Shockwave Medical while Novo Nordisk is buying Catalent, a CDMO organization.

Best biotech stocks to buy and hold in 2024: VKTX, SANA, RXRX

By 2029, Recursion Pharmaceuticals could have multiple products. There is also a chance it could be facing some serious challenges.

Where Will Recursion Pharmaceuticals Be in 5 Years?

Dr. Khan, formerly the Chief Data Science Officer and Global Head of Strategy and Portfolio, Innovative Medicine R&D at Johnson & Johnson (J&J), will also join Recursion's Board of Directors Dr. Khan, formerly the Chief Data Science Officer and Global Head of Strategy and Portfolio, Innovative Medicine R&D at Johnson & Johnson (J&J), will also join Recursion's Board of Directors

Recursion Appoints Najat Khan, PhD, as Chief R&D Officer and Chief Commercial Officer

Actinium Pharmaceuticals

CorMedix

Fulcrum Therapeutics Inc

Marinus Pharmaceuticals

Ocular Therapeutix

Outlook Therapeutics Inc

The broader medical therapeutic sector is already volatile so it stands to reason in some sense to consider under-$10 biotech stocks. Imagine you acquired shares of a popular, richly priced enterprise, only for the underlying security to suffer due to a poor clinical result.

Biotech on a Budget: 7 Stocks Under $10 With Huge Potential

Coinbase

Nextdoor

Known for her focus on innovative disruption, Cathie Wood has become one of the biggest names in capital management. With her firm, ARK Invest, Wood has created custom exchange-traded funds focused on aggregating high-potential stocks.

Wall Street Favorites: 3 Cathie Wood Stocks With Strong Buy Ratings for April 2024

News for Recursion Pharmaceuticals Stock (RXRX)